Drug Trial Radar · NCT07905105
A Study of CYT-1010 in Healthy Volunteers and Participants With Acute Pain After Third Molar Extraction
Last checked: Nov 19, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
32
Planned (sponsor's estimate)
Start
Sep 25, 2026
Primary completion
Oct 2027
Study completion Oct 2027
Sponsor
- Lead sponsor
- Cytogel Pharma, LLCIndustry
- Sponsor type
- Industry
- First posted
- Oct 29, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary objective of this trial is to assess the safety and tolerability of single, ascending doses of CYT-1010 in healthy male and female volunteers and in the treatment of acute postoperative pain after third molar extraction.
Conditions
- Acute Postoperative Pain
- Dental Pain
Interventions
CYT-1010Drug
Single intravenous (IV) dose of 5 mg or 10 mg CYT-1010.
PlaceboDrug
20% hydroxypropyl-β-cyclodextrin, approximately 0.01 N HCl, IV sterile injection delivered as a single IV dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-Emergent Adverse EventsTime frame: From trial drug administration through Day 7
- Sum of Pain Intensity Differences (SPID) Over 2 Hours (SPID2) in Dental Pain ParticipantsTime frame: From pre-dose to 2 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
CenExel SLC
Salt Lake City, Utah · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.